Quality Stocks Daily Newsletter (12/19/2008)

NexMed Inc. (NEXM)

Today, Stock Egg reported on NexMed Inc. (NEXM), Bull in Advantage, Breakout Investments, and Penny Stocks Finder Blog did earlier, and we are highlighting the Company here at the QualityStocks Daily Newsletter.

Founded in 1987, NexMed, Inc. is a drug developer that is using their proprietary NexACT® drug delivery technology to produce a variety of new medical treatments. The Company lists on the NASDAQ Capital Market and has their headquarters in East Windsor , New Jersey . They offer pharmaceutical companies the opportunity to incorporate NexACT® into their existing drugs. This allows enterprises to save on research and development costs while developing new transdermal products.

The NexACT® transdermal drug-delivery technology is for enhancing the absorption of an active drug through the skin and enabling concentrations of the drug to penetrate the desired site of the skin or extremity. NexACT® drug delivery technology offers fast onset of action, patient friendly route of delivery, little to no side effects, and improved clinical effectiveness. The NexACT® penetration enhancers are structurally similar to and biologically compatible with a person's skin structure. They are non-toxic, biodegradable, and enable drug candidates to overcome the skin or mucosal membranes. The Company's NexACT® technology is applicable to the development of transdermal creams, gels, ointments, lotions, solutions, and intranasal sprays.

NexMed Inc. is developing their NM100060, a nail lacquer treatment for onychomycosis. They are also developing Femprox, an alprostadil-based cream product intended for the treatment of female sexual arousal disorder. In November of 2007, NexMed announced a licensing agreement with Warner Chilcott, Ltd. for the exclusive U.S. rights to their topically applied treatment Vitaros® for erectile dysfunction (ED).

Last month, NexMed announced that they received approval by the State of New Jersey to sell a portion of their state tax credits and net operating losses (NOLs) pursuant to the Technology Tax Certificate Transfer Program. The Company has approval to sell $1,053,547 in 2008.

"We are extremely pleased that NexMed has been selected to participate in this year's program. The sale, which is expected to net approximately $937,000 in cash to the Company by mid-December, will further strengthen our capital reserves," said the Company's Chief Financial Officer, Mark Westgate.

NexMed Inc. (NEXM) closed Thursday's session at $0.15 up $0.02 or 15.47 percent. Volume was 27,213,569 for a 3-month average volume of 594,495.

RF Micro Devices Inc. (RFMD)

Today, Stock Stars and Greenbackers reported on RF Micro Devices Inc. (RFMD), and we are highlighting them as well here at the QualityStocks Daily Newsletter.

RF Micro Devices, Inc. is a designer and manufacturer of high-performance semiconductor components. Trading on the NASDAQ, they operate in the Semiconductor-Integrated Circuits industry within the Technology sector and have their corporate headquarters in Greensboro, North Carolina. Their products provide worldwide mobility and enhanced connectivity as well as support advanced functionality in the cellular handset, wireless infrastructure, wireless local area network (WLAN), CATV/broadband, and aerospace and defense markets.

RF Micro Devices is an ISO 9001- and ISO 14001- certified manufacturer. They have global engineering, design, sales, and service facilities. The Company designs, develops, manufactures, and markets proprietary radio frequency integrated circuits (RFIC's). Their product mix includes amplifiers, mixers, modulators/demodulators, and single-chip receivers, transmitters and transceivers. Their strategy is to focus on wireless markets by offering a great selection of standard and custom-designed RFIC's so they can position themselves as a "one-stop" solution for their customers' RFIC needs.

The company began in 1991 through the efforts of William J. Pratt, Powell T. Seymour, and Jerry D. Neal. RF Micro Devices Inc. grew from a small design shop into a global leader in wireless technology, and they are a premier component supplier. They provide the world's leading wireless manufacturers the critical components that enable wireless devices to transmit and receive signals.

Yesterday, the Company announced they intend to take action to streamline operations and reduce GaAs semiconductor manufacturing costs. RFMD® expects the actions will take effect in the March 2009 quarter and will positively influence cash flow in the Company's fiscal 2010 beginning March 29, 2009.

Bob Bruggeworth, President, and CEO of RF Micro Devices Inc. (RFMD), said, "RFMD is taking prudent and decisive actions to match manufacturing capacity to anticipated demand during the current recessionary environment. By reducing RFMD's manufacturing cost structure, these actions are expected to positively impact cash flow by approximately $15 million in fiscal 2010. Because existing facilities will be reduced or idled, RFMD will retain the capacity and flexibility necessary to respond to increases in customer demand as the recession wanes and as the Company's markets return to growth."

RF Micro Devices Inc. (RFMD) closed at $0.90, which was up $0.01 or 1.12 percent. Their volume was 2,092,927 shares for a 3-month average volume of 5,545,650 shares.

HST Global Inc. (HSTC)

Today we are highlighting HST Global Inc. (HSTC) as "One to Watch" here at the QualityStocks Daily Newsletter.

Headquartered in Hampton , Virginia , HST Global Inc. is a development-stage biotechnology company. They acquire and develop innovative products for the treatment of cancer and other life threatening illnesses. The Company lists on the OTCBB and has a current market capitalization of $66.86 million. Their corporate focus is on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer. They then develop those drug candidates for commercial use. HST Global Inc. is also developing a network of Wellness Centers worldwide.

HST is one of a small number of companies working to create relationships and partnerships for the development of prescription drugs from natural sources. The Company has a holistic perspective and believes that the synergy amongst the parts of a plant or substances from other natural sources have significant value. They believe that plant co-factors, instead of a single chemical entity, will increase the safety and efficacy of the medicines they make.

The Company has focused their efforts on Salicinium, which is their clinical stage drug candidate. They have the rights to a pre-clinical outcome-based study using the homeopathic remedy trade named "salicinium". This is a natural plant-derived substance that is both oral and a parenteral active inhibitor of certain fermenting enzyme dynamics in cancer cells. Clinical studies demonstrate that salicinium alters malignant cell fermentation dynamics, blocks cell division, and causes fermenting cancer cells to lose their ability to withstand innate immune reactions.

Last month, HST Global announced plans for the first quarter of fiscal 2009. They are launching their wholly owned division dedicated to opening their own brand of Cancer Treatment Centers. This strategy will enable the Company to address the challenges individuals face in the treatment of cancer in the later stages.

Ronald Howell, President, and CEO of HST Global, Inc. stated, "There is a growing population of individuals experiencing the lack of available alternatives in treating late stage cancer. We have been working with a number of highly visible Physicians that are and have developed successful protocols that are meeting with success in the treatment of this population. As such, we will begin opening a privately branded chain of Cancer Treatment Centers strategically positioned around the world through a new wholly owned subsidiary."

Yesterday, HST Global Inc. announced the appointment of Dr. Kyl Smith to their Scientific Board. He is a noted researcher, inventor, lecturer, author, and scientist. He is well known as the inventor of Focus Factor®, the number-one selling brain support product in North America for the last seven years.

We have HST Global Inc. (HSTC) on our radar screens as "One to watch", here at the QualityStocks Daily Newsletter.

HST Global Inc. (HSTC) closed today's session at $3.20 for no change. Volume was 1,175 for a 3-month average volume of 1,803.03.

Ligand Pharmaceuticals Incorporated (LGND)

The Tycoon Report reported on Ligand Pharmaceuticals Incorporated (LGND) and we choose to as well here at the QualityStocks Daily Newsletter.

Headquartered in San Diego, California, Ligand Pharmaceuticals Inc. is an emerging research, development, and royalty-driven biotechnology company. Ligand discovers and develops new drugs that address critical unmet medical needs. These are for patients with muscle wasting, frailty, hormone-related diseases, osteoporosis, inflammatory diseases, and anemia. They base their proprietary drug discovery and development programs on their leadership position in gene transcription technology. Ligand Pharmaceuticals Incorporated trades on the NASDAQ Global Market.

Ligand is working to solve unmet medical needs in therapeutic areas. These include developing PROMACTA™ (eltrombopag) and VIVIANT™ (bazedoxifene). In the area of TPO Mimetics, PROMACTA™ (eltrombopag) is a small-molecule TPO mimetic that is being developed by GlaxoSmithKline for thrombocytopenia. The FDA granted, on November 20, 2008, accelerated approval of PROMACTA™ for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP), who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

GlaxoSmithKline also reported positive Phase II data in patients with thrombocytopenia associated with hepatitis C. A Phase II study in patients with chemotherapy-induced thrombocytopenia is complete. A Phase III study is ongoing in chronic liver disease and a Phase I study is ongoing in patients with sarcoma.

VIVIANTTM (bazedoxifene) is undergoing development by Wyeth as a monotherapy for osteoporosis. Wyeth is also developing APRELA™, which is bazedoxifene in combination with PREMARIN®, for osteoporosis prevention and vasomotor symptoms of menopause.

Ligand's pharmaceutical partnerships include ones with King Pharmaceuticals, GlaxoSmithKline, Wyeth, Pfizer Inc., and TAP Pharmaceuticals Products Inc. Their research and development programs are built on their proprietary intracellular (IR) technology. Intracellar technology is a technology that has generated compounds including LGD-4665 and partnered products. These compounds modulate gene transcription by affecting key cellular or intracellular receptor targets discovered using IR technology.

Today, Ligand Pharmaceuticals Incorporated announced that they entered into an exclusive, worldwide license agreement with GlaxoSmithKline. Ligand has licensed worldwide exclusive rights to their LGD-4665 product candidate and their other thrombopoietin (TPO)-related molecules to GlaxoSmithKline. LGD-4665 currently is in Phase II for treatment of thrombocytopenia, a condition of low-platelet levels commonly associated with a diverse range of clinical disorders.

GlaxoSmithKline will pay Ligand $5 million as an upfront license fee, up to $158 million in development and commercial milestones, and a 16 percent royalty on net sales. In the first year of sales, royalties will be one-half of the regular royalty rates.

Today, Ligand Pharmaceuticals Incorporated (LGND) closed at $2.47 down $0.07 or 2.76 percent. Volume was 588,168 for a 3-month average volume of 806,697.

Opexa Therapeutics Inc. (OPXA)

HotOTC.com and Standout Stocks reported earlier on Opexa Therapeutics Inc. (OPXA) and we highlight the Company here at the QualityStocks Daily Newsletter.

Opexa Therapeutics Inc. develops and commercializes cell therapies to treat autoimmune diseases such as multiple sclerosis (MS) and diabetes. Trading on the NASDAQ Capital Market, Opexa has their corporate headquarters in The Woodlands, Texas . Formerly known as PharmaFrontiers Corp., and founded in 2003, the Company changed their name to Opexa Therapeutics, Inc. in 2006.

Opexa Therapeutics Inc. focuses on autologous cellular therapy applications of their proprietary T-cell and stem cell therapies. Their lead product is Tovaxin®, a T-cell therapy for MS, which is in Phase IIb trials. It is a T-cell vaccine for MS that is tailored specifically to each patient's disease profile. Top-line results from the Phase IIb Tovaxin® for Early Relapsing Multiple Sclerosis (TERMS) study demonstrated a positive trend in reduction in annualized relapse rate for Tovaxin® -treated patients as compared to a placebo. In addition, there were no serious adverse events related to Tovaxin® treatment.

The Company plans to complete their full analysis of all data from the TERMS study. Based on the TERMS study results, they expect to conduct a Phase II closeout meeting with the United States Food and Drug Administration during the first half of 2009. This meeting, and comprehensive results of the TERMS study, will provide the Company guidance in their plans to advance Tovaxin® into Phase III development.

Opexa also has their Adult Stem Cell Program concerning diabetes.
Their technology in this area allows for the production of multi-potent cells generated from patients' white blood cells. This provides a means to differentiate these stem cells into other tissue types such as pancreatic areas. A patient's own cells could minimize the threat of rejection. The generation of insulin-secreting pancreatic-like cells is the focus of the initial application of this program.

In late October, Opexa reported additional positive data from their Phase IIb TERMS clinical trial. This analysis focused on a prospective group of patients with an annualized relapse rate of greater than one at study entry, which is comparable to annualized relapse rate baselines of patients in previous Tovaxin® studies. The findings demonstrated a statistically significant improvement in disability as measured by the Expanded Disability Status Scale for patients treated with Tovaxin® as compared to those receiving placebo.

Opexa Therapeutics Inc. (OPXA) closed Thursday's session at $0.164 up $0.014 or 9.33 percent. Volume was 26,750 for a 3-month average volume of 90,264.60.

Genta Incorporated (GNTA)

Today, Stock Stars reported on Genta Incorporated (GNTA), Bull in Advantage did last week, Small Cap Voice and Knobias did earlier, and we are highlighting them as well here at the QualityStocks Daily Newsletter.

Founded in 1988, Genta Incorporated is a biopharmaceutical company in the biotechnology industry. They have a diversified product portfolio that focuses on delivering new products for the treatment of cancer patients. Headquartered in Berkeley Heights , New Jersey , Genta Incorporated trades on the OTCBB.

Genta has two major research programs. These are DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from their DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma.

The leading drug in their Small Molecule program is Ganite® (gallium nitrate injection). Genta is exclusively marketing this drug in the United States for treatment of patients with cancer related hypercalcemia, which is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, which is a potential treatment for diseases associated with accelerated bone loss. This is currently in clinical trials. Genta is also developing tesetaxel, an oral semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel.

On December 4, Genta Incorporated announced that they received notice from the U.S. Food and Drug Administration (FDA) that tesetaxel received designation as an "Orphan Drug" for treatment of patients with advanced melanoma. Orphan drug status allows for a period of marketing exclusivity, certain tax benefits, and an exemption from certain fees upon submission of a New Drug Application.

Tesetaxel is a late Phase 2 oncology product. It has demonstrated anticancer activity in its initial clinical trials, and has not been associated with severe infusion reactions linked with other taxanes. Nerve damage has not been a prominent side effect of tesetaxel as it can be with other oral taxanes. Tesetaxel offers opportunities to improve patient convenience, safety, and anticancer activity. More than 250 patients worldwide have received treatment with oral tesetaxel in Phase 1 and Phase 2 clinical trials.

Today, Genta Incorporated (GNTA) closed trading at $0.0027, for no change. Volume was 89,178,291 shares for a 3-month average of 3,651,570 shares.

Xinhua Finance Media Limited (XFML)

Stock Stars, Stock Egg, and Hot OTC reported previously on Xinhua Finance Media Limited (XFML), and we choose to report on the Company today here at the QualityStocks Daily Newsletter.

Trading on the NASDAQ Global Market, Xinhua Finance Media Limited is a leading media group in China targeting the country's upwardly mobile demographic. They do this via television, radio, newspapers, magazines, outdoor, online, and other media assets and specialize in connecting and entertaining the people of China . The Company has their headquarters in Beijing , China . Xinhua also has other offices and affiliates in Beijing , Shanghai , Guangzhou , Shenzhen, and Hong Kong .

Xinhua Finance Media Limited's business focuses on entertainment and financial information. They sell advertising around the content on the broadcast and print outlets that are part of their XFMedia platform. They reach roughly 210 million television viewers and a 125 million strong radio audience. They also can reach more than 480 million potential mobile phone users and readers of leading magazines and newspapers.

The Company's Broadcast Group produces and syndicates high-quality content. They distribute this content to audiences and clients through television and radio broadcast channels throughout China , from which they sell advertising. Their Print Group designs and places advertising in local and nationwide publications and provides consulting services. Xinhua Finance's Advertising Group is an advertising agency that produces and places advertising for campus billboards, outdoor media, websites, television, radio, newspaper, and magazines in China. They also provide services that help advertisers to organize marketing events at shopping malls, campuses, clubs, and entertainment outlets.

Last month, Xinhua Finance Media announced that their subsidiary, Xinhua Media Entertainment is unveiling their initial expected film slate. This is for the next three years and represents the Company's long-term commitment to display Chinese culture, top Chinese talents, artisans, and production crews. They look to highlight them on the world stage via major collaborations with premier filmmakers, screenwriters, and producers from Hollywood .

Xinhua Finance Media Limited (XFML) closed today's session at $0.63, which was up $0.04 or 6.78 percent. Volume was 160,097 for a 3-month average of 336,811.

Carbon Sciences Inc. (CABN)

Investor Ideas and Red Chip reported yesterday on Carbon Sciences Inc. (CABN) and we are highlighting the Company today here at the QualityStocks Daily Newsletter.

Carbon Sciences Inc. is a company innovating in the Waste Management industry. Their focus is on developing their technology to convert carbon dioxide into a form that does not contribute to the warming of the earth's environment. The Company began as Zingerang Inc. in 2006, and changed their name to Carbon Sciences Inc. in April 2007. The Company's corporate headquarters are in Santa Barbara , California and they trade on the OTCBB.

Carbon Sciences Inc. believes that by eliminating harmful CO2 from power plants and industrial factories, there will be a reduction in global warming. They see the transformation of damaging CO2 into useful carbon products with their patent-pending technology. They also see this technology as helping industries be more environmentally conscious. Carbon Sciences is developing a technology to transform CO2 emissions into the basic fuel building blocks required to produce gasoline, diesel fuel, jet fuel, and other fuels. They are developing a highly scalable biocatalytic process to meet global fuel needs.

This past spring, Carbon Sciences announced their first application targeting a near term multi-billion dollar global market. This initial application of Carbon Sciences Inc.'s technology is a process to transform CO2 into a high value chemical compound, currently used in the manufacture of paper, pharmaceuticals, and plastics. Carbon Sciences' clean technology process will be carbon neutral. The demand for this compound - Precipitated Calcium Carbonate (PCC) - is on the rise due to increased global paper consumption and construction in Asian markets.

On Monday, Carbon Sciences announced that representatives of oil refineries expressed a high level of interest in Carbon Science's technology at the ACI Downstream CO2 & Energy Efficiency Forum held December 3-5 in Istanbul , Turkey .

Derek McLeish, the Company's CEO and a featured speaker at the Conference, said, "Our breakthrough technology for transforming CO2 to hydrocarbons fits refineries' needs in today's environmentally conscious world. Instead of emitting hundreds of millions of tons of CO2 into the atmosphere and face potential legal and economic penalties, oil refineries can use our technology to transform their CO2 streams directly into fuel building blocks.”

Carbon Sciences Inc. (CABN) closed today's trading at $0.20, for no change. Their volume was 19,900, and their 3-month average volume is 118,820.
The QualityStocks Company Corner
Nexia Holdings, Inc. (NXHD)
MyECheck (MYEC)
Bravo Resources (BRPNF)
Axial Vector Energy Corp. (AXVC)

Nexia Holdings, Inc. (NXHD)

The QualityStocks Daily Newsletter would like to spotlight Nexia Holdings, Inc. (NXHD) Today, Nexia Holdings, Inc. closed trading at $0.0002, which was up $0.0001 or 100.00 percent from yesterday's close. Their volume today was 14,772,000 shares.

Nexia Holdings, Inc. announced today that Wasatch Capital Corporation, a subsidiary of Nexia's, has appointed three new officers to manage the real estate operations that will be expanding under Wasatch's ownership.

Nexia Holdings, Inc. is a diversified holdings company with operations in health and beauty, fashion retail, and real estate. Currently, the company owns two salons, one retail store, one online retail store and three commercial properties.

The two salons, Landis Lifestyle Salon and Landis Salon, are both located in Utah. Landis Lifestyle Salon, located in Salt Lake City, is an Aveda™ Lifestyle Salon, while Landis Salon, located in Bountiful, is an Aveda™ Concept Salon. Nexia plans to grow the Landis brand to a national level with up to 5 locations in the Salt Lake region before executing a national expansion plan that could include franchise opportunities.

The retail store, operated by subsidiary Black Chandelier, sets itself apart from clothing giants such as The Gap, Hot Topic, and Target by offering eco-friendly fabrics, in-house sewers and silk screeners, and crazy models like Lisa D'Amato. The store was designed to be a tourist attraction that offers an innovative retail shopping experience.

Nexia Holdings, Inc. also has more than a decade of experience acquiring undervalued properties in the area of Salt Lake City. The company's existing portfolio includes the historic Wallace-Bennett Building (a 38,000 sq. ft. multi-story office building in Salt Lake City), a 7,000 sq. ft. one-story retail building on State Street in Salt Lake City, and 100,000 sq. ft. building on Sam's Boulevard in Kearns. The company also owns seven small parcels of undeveloped raw land in Utah and Kansas. Disclaimer

Nexia Holdings, Inc. Blog

Nexia Holdings, Inc. News:

Nexia Assembles New Real Estate Acquisition Team

Nexia Ranked in Top 40 Public Companies by Utah Business Magazine

Nexia Acquires Two Additional Residential Properties

MyECheck (MYEC)

The QualityStocks Daily Newsletter would like to spotlight MyECheck Inc. (MYEC) Today MyECheck, Inc. closed trading at $2.00, which was up $0.30 or 17.65 percent. Their volume today was 8,500 shares. Their 3-month average volume is 11,067.70 shares.

MyECheck (MYEC) announced that they have developed and launched their newest software upgrade called osCommerce Plug-In for Quick Open Source Integration. MyECheck's new software allows osCommerce users to gain easy access to MyECheck services by simply downloading and installing software from http://oscommerce.com/ .

MyECheck offers online merchants, call centers, billers, retail POS and RDC/back office applications an array of comprehensive Check 21 imaging, processing and related solutions. The company was created to meet the demand for an alternative payment solution to credit cards when buying products and services online.

The company has made great strides since its inception four years ago. MyEcheck has stayed committed to enhancing its offerings as well as launching brand new services, making it a leader in Check 21 solutions today. The company is known for offering the most comprehensive suite of electronic check processing services in the industry.

MyECheck differs from ACH by increasing capability with consumer accounts, expediting the clearing process, and providing exceptional charge-back protection. The regulations imposed by Check 21 law and Uniform Commercial Code (UCC state law) are more favorable to the recipient than those governing ACH transactions, allowing simplification, easier compliance and reduced costs. Disclaimer

MyECheck Blog

MyECheck News:

MyECheck Offers osCommerce Plug-In for Quick Open Source Integration

MyECheck Signs Vacation Renter Solutions, LLC to Its Electronic Transaction Processing Software

MyECheck Launches Superior Business Network Yellow Pages on Its Check 21 Patented Software -- SBN Powers Over 10,000 Websites

Bravo Resources Partners Ltd. (BRPNF)

The QualityStocks Daily Newsletter would like to spotlight Bravo Resources Partners Ltd. (BRPNF) Today, Bravo Resources Partners Ltd. closed trading at $0.03, which was up $0.01 or 50.00 percent from yesterday's close. Their volume today was 159,000 shares.

Bravo Resources Partners Ltd. recently appointed Mr. Jefferey Cox as President and CEO of the company, and has also signed a memorandum of understanding with a significant property in Ghana. Initial due diligence indicates a vast gold reserve on the property. The company anticipates keeping shareholders updated as negotiations progress to the closure of this agreement as well as the resulting forward action on mining activities.

Ghana, Africa has been a producer of gold since the 16th century and today boasts one of the largest and richest reserves of gold in the world. The country's natural resources have enabled it to carve out a market for itself in the competitive international market place. Ghana is recognized as Africa's second largest gold miner and produced nearly 2.5 million ounces of the metal in 2007.

Most gold mining before the mid-nineteenth century was alluvial. Modern gold mining began when European concessionaires imported heavy machinery and started working in the western areas of present-day Ghana. Since the beginning of the twentieth century, modern mining in the Gold Coast has been pursued as a large-scale venture, requiring capital investment.

AGC, the country's largest producer, planned major expansions in the early 1990s with capital investment from World Bank loans. In 1991, the company discovered new reserves estimated at more than 8 million ounces, in addition to its known reserves of 22.3 million ounces. AGC wasn't the only Ghana company to benefit from the country's rich resources, as Teberebie, Billiton Bogoso, State Gold Mining Corporation, Southern Cross Mining Company, Goldenrae, Bonte, and Okumpreko all increased production. Disclaimer

Bravo Resources Partners Ltd. Blog

Bravo Resources Partners Ltd. News:

Bravo Resource Partners Negotiates M.O.U. on Gold Mine With Vast Reserves in Ghana, Africa

Axial Vector Energy Corporation (AXVC)

The QualityStocks Daily Newsletter would like to spotlight Axial Vector Energy Corp. (AXVC) Today, Axial Vector Energy Corp. closed trading at $0.13, which was up $0.02 or 18.18 percent. Their volume today was 147,365 shares. Their 3-month average volume is 127,798.

Axial Vector Energy Corporation (AXVC) a publicly traded, development-stage company providing global energy solutions, develops multi-fuel engines and generators for use primarily in military and commercial applications.

Founded in 2002, with headquarters in Portland, Oregon, Axial Vector - through a joint venture agreement with Adaptive Propulsion Systems, LLC - develops and manufactures their engines and generators with an eye toward environmental responsibility and social benefit.

Axial Vector Energy Corporation owns, develops and licenses a technologically advanced suite of internal combustion engines and electric power generation modules. The company has also developed the world's only “coreless” no iron electric motors, which consume one half the electricity of conventional electric motors.

These cutting-edge technologies are focused on fulfilling global engine and energy needs by delivering greater fuel-efficiency, cost effectiveness, versatility, and environmental sensitivity than ever before in venues from the commercial to the industrial, including the vehicular and military sectors. Disclaimer

Axial Vector Energy Corporation Blog

Axial Vector Energy Corporation News:
Axial Vector Energy Corp. Summarizes Highlights of Investor Conference Call

Axial Vector Energy Corporation Announces Investor Conference Call Hosted by Company President/CEO, Sanjai Chhaunker

Axial Vector Announces the Formation of United States Wind Power Industry Joint Venture

Our name, QualityStocks.net, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. We believe strong management and vision for the future are crucial for any company to be successful. Timing is everything and we help investors succeed by providing an objective, broad-based view of the SmallCap markets on a daily basis.

Please see disclaimer on QualityStocks.net website: http://disclaimer.qualitystocks.net